Published on 22 Jun 2023 on Simply Wall St. via Yahoo Finance
The past five years for Cara Therapeutics (NASDAQ:CARA) investors has not been profitable
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Cara Therapeutics, Inc. (NASDAQ:CARA) for five years would be nursing their metaphorical wounds since the share price dropped 79% in that time. And it's not just long term holders hurting, because the stock is down 55% in the last year. The falls have accelerated recently, with the share price down 39% in the last three months.
With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.
Check out our latest analysis for Cara Therapeutics